GlaxoSmithKline Pharmaceuticals Ltd banner

GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO

Watchlist Manager
GlaxoSmithKline Pharmaceuticals Ltd Logo
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Watchlist
Price: 2 440 INR -1.29% Market Closed
Market Cap: ₹413.4B

GLAXO's latest stock split occurred on Sep 11, 2018

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

Before the split, GLAXO traded at 3590.1 per share. Afterward, the share price was about 1568.3171.

The adjusted shares began trading on Sep 11, 2018. This was GLAXO's 3rd stock split, following the previous one in Jun 23, 1997.

Last Splits:
Sep 11, 2018
2-for-1
Jun 23, 1997
8-for-5
May 31, 1995
2-for-1
Pre-Split Price
1 610.0241 3 590.1
Post-Split Price
1 568.3171
Before
After
Last Splits:
Sep 11, 2018
2-for-1
Jun 23, 1997
8-for-5
May 31, 1995
2-for-1

GlaxoSmithKline Pharmaceuticals Ltd
Stock Splits History

GLAXO Stock Splits Timeline
Sep 11, 2018
Sep 11, 2018
Split 2-for-1
x2
Pre-Split Price
1 610.0241 3 590.1
Post-Split Price
1 568.3171
Before
After
Jun 23, 1997
Jun 23, 1997
Split 8-for-5
x1.6
Pre-Split Price
N/A
Post-Split Price
187.2619
Before
After
May 31, 1995
May 31, 1995
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
187.2619
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 27, 2026
M
Mitsubishi Logisnext Co Ltd
TSE:7105
1-for-22962728
/22962728
1529 999999.9999 JPY N/A
Apr 27, 2026
Intsig Information Co Ltd
SSE:688615
1-for-1
x1
180.14 127.0214 CNY 128 128 CNY
Apr 27, 2026
Nousouken Corp
TSE:3541
1-for-550000
/550000
763 763 JPY N/A
Apr 27, 2026
F
Friendly Corp
TSE:8209
1-for-1355800
/1355800
312 999999.9999 JPY N/A
Apr 27, 2026
I
IA Inc
KOSDAQ:038880
1-for-10
/10
135 1350 KRW 1231 1231 KRW
Load More

GlaxoSmithKline Pharmaceuticals Ltd
Glance View

Market Cap
413.4B INR
Industry
Pharmaceuticals

GlaxoSmithKline Pharmaceuticals Ltd., a subsidiary of the global healthcare juggernaut GSK, stands as a pillar in the pharmaceutical industry, with roots deeply entrenched in innovation and a robust pipeline of healthcare products. This company weaves a narrative of relentless pursuit in the creation and distribution of a wide variety of medicines and vaccines, aimed at improving the quality of human life. Operating predominantly in the areas of pharmaceuticals, vaccines, and consumer healthcare, GSK integrates cutting-edge research with strategic collaborations. This enables them to address pressing medical needs, such as respiratory diseases, HIV, infectious diseases, and oncology, amongst others, thereby leveraging their expertise to cater to diverse healthcare demands. The heart of their revenue generation lies in the seamless amalgamation of research acumen and market presence. By investing significantly in research and development, GSK continually introduces groundbreaking therapies and health solutions. The company has adeptly structured its operations to create a strong global presence, which not only involves selling directly to healthcare providers and governments but also innovating its supply chain to maximize reach. Moreover, GSK's astute marketing efforts ensure that their products are not just effective but also attuned to consumer needs. With a focus on sustainable growth and transformative medicines, GSK’s story becomes a testament to how science-driven strategies can forge pathways to a healthier world while simultaneously fueling the company’s economic engine.

GLAXO Intrinsic Value
1 376.65 INR
Overvaluation 44%
Intrinsic Value
Price ₹2 440
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett